About 3,458 results

ALLMedicine™ Acromegaly Center

Research & Reviews  1,195 results

Virtual education programming for patients with acromegaly: a pilot study.
European Journal of Endocrinology; Geer EB, Kilgallon JL et. al.

Jan 16th, 2022 - To assess the impact of virtual education programming for patients with acromegaly. We conducted a mixed methods study to evaluate patient attitudes, examine if patient-centered educational forums change these attitudes, and determine the role of ...

Personalized Medical Treatment in Patients with Acromegaly: A Review.
Endocrine Practice : Official Journal of the American Col... Ting Lim DS, Fleseriu M

Jan 16th, 2022 - Acromegaly is associated with significant morbidity and mortality if not appropriately treated. In addition to insulin-like growth factor 1 (IGF-1) and growth hormone (GH) normalization, and tumor shrinkage, treatment goals include symptom relief,...

Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the A...
Pituitary Salvatori R, Maffei P et. al.

Jan 14th, 2022 - To report the effects of pegvisomant (PEGV) treatment on patient-reported outcomes in acromegaly patients. We conducted an extension study of an open-label, multinational, non-interventional study (ACROSTUDY) evaluating the long-term safety and ef...

Long-Term Outcomes of Patients with Acromegaly - A Report from the Swedish Pituitary Re...
European Journal of Endocrinology; Arnardóttir S, Järås J et. al.

Jan 11th, 2022 - To describe treatment and long-term outcomes of patients with acromegaly from all health-care regions in Sweden. Analysis of prospectively reported data from the Swedish Pituitary Register of 698 patients (51% females) with acromegaly diagnosed fr...

see more →

Guidelines  5 results

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) ...
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.

Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Expert consensus document: A consensus on the medical treatment of acromegaly.
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

American Association of Clinical Endocrinologists medical guidelines for clinical pract...
Endocrine Practice : Official Journal of the American Col... Katznelson L, Atkinson JL et. al.

Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

AME Position Statement on clinical management of acromegaly.
Journal of Endocrinological Investigation; Cozzi R, Baldelli R et. al.

Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,

Guidelines for acromegaly management: an update.
The Journal of Clinical Endocrinology and Metabolism; Melmed S, Colao A et. al.

Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...

see more →

Drugs  26 results see all →

Clinicaltrials.gov  60 results

Genetic Studies of Insulin and Diabetes

Dec 27th, 2021 - Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, type 2 diabetes, and acromegaly), the target cells are resistant to insulin action. Insulin resistance leads to metabol...

Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery

Dec 8th, 2021 - At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basi...

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Dec 6th, 2021 - The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to contin...

Acromegaly Combination Treatment Study

Sep 28th, 2021 - Subjects will be stratified based on prior response to SRL therapy and then randomized to one of three treatment arms. The study will begin when the combination of octreotide LAR or lanreotide and pegvisomant is first administered. Study visits wi...

Nasal Packing Following Endoscopic Endonasal Pituitary Resection

Sep 9th, 2021 - BACKGROUND AND CLINICAL SIGNIFICANCE Over the past decade, the surgical method for removing pituitary tumors has shifted from a microscopic resection technique performed exclusively by a neurosurgeon, to an endoscopic resection done as a team with...

see more →

News  93 results

Oral Octreotide Shows Promise as Alternative to Injections for Acromegaly

Jan 10th, 2022 - NEW YORK (Reuters Health) - Many patients with acromegaly may do as well on oral octreotide treatment as they do on injectable somatostatin receptor ligands (iSRLs), an industry-sponsored phase-3 trial suggests. Oral octreotide is the first oral m...

Association of Circulating IGF-I with Common Non-cancerous Conditions

Nov 15th, 2021 - Takeaway Circulating insulin-like growth factor-I (IGF-I) was associated with several common conditions (other than cancer), including a positive association with carpal tunnel syndrome and inverse associations with varicose veins and iron deficie...

FDA Eyes Oral Testosterone; Phase II Success for Novel Osteoporosis Tx

Mar 14th, 2021 - The FDA accepted a new drug application and set a review date of October 31 for Marius Pharmaceuticals' Kyzatrex, an oral testosterone undecanoate softgel, for primary and secondary male hypogonadism. The Endocrine Society released a new scientifi...

Physicians' Financial News: March 2008

Dec 5th, 2020 - Click here to view as PDF. Novartis Leverages Formidable Size and Pipeline to Maintain Strong Oncology Position Novartis—listed on New York, Swiss, and London stock exchanges—was formed in March 1996 by the combination of Sandoz and Ciba-G...

FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors

Dec 4th, 2020 - Alexandria Phan, MD The FDA has approved lanreotide (Somatuline Depot Injection) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-...

see more →

Patient Education  4 results see all →